Clinical Trials Browser

Phase 2 × Overall Survival × anlotinib × Clear all

NCT05218629 2023-03-29

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

Phase 2 Unknown

Overall Survival